Solid Tumors Clinical Trials in Detroit, Michigan

8 studies are recruiting for solid tumors in Detroit, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

   The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Karmanos Cancer Institute ( Site 0047), Detroit, Michigan

   Locations

   782 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT03486873 on ClinicalTrials.gov

2. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

   The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Investigative Site US010, Detroit, Michigan

   Locations

   229 in total

   Run by

   Incyte Corporation

   See if you can join NCT07522073 on ClinicalTrials.gov

3. A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

   The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Detroit, Michigan

   Locations

   25 in total

   Run by

   Arcus Biosciences, Inc.

   See if you can join NCT05536141 on ClinicalTrials.gov

4. A Study of ZL-1310 in Participants With Selected Solid Tumors

   A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Karmanos Cancer Center, Detroit, Michigan

   Locations

   23 in total

   Run by

   Zai Lab (Shanghai) Co., Ltd.

   See if you can join NCT06885281 on ClinicalTrials.gov

5. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

   A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   16 in total

   Run by

   Tyra Biosciences, Inc

   See if you can join NCT06915753 on ClinicalTrials.gov

6. A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

   The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount

   Stage

   Phase 1

   Ages

   18 and older

   Site

   GSK Investigational Site, Detroit, Michigan

   Locations

   65 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06431594 on ClinicalTrials.gov

7. S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

   The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011 with or without pembrolizumab. The primary objective of Parts B and C is to evaluate the antitumor activity of …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Health Center, Detroit, Michigan

   Locations

   8 in total

   Run by

   Shionogi

   See if you can join NCT05101070 on ClinicalTrials.gov

8. JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

   This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Health System, Detroit, Michigan

   Locations

   8 in total

   Run by

   Jacobio Pharmaceuticals Co., Ltd.

   See if you can join NCT05490472 on ClinicalTrials.gov